GWAS-identified colorectal cancer susceptibility locus associates with disease prognosis

详细信息    查看全文

• 作者：Jinliang Xing^a ; Ronald E. Myers^b ; Xianli He^c ; Falin Qu^c ; Feng Zhou^c ; Xi Ma^a ; Terry Hyslop^d ; Guoqiang Bao^c ; Shaogui Wan^b ; Hushan Yang^b ; ^{hushan.yang@jefferson.edu"" rel=""nofollow} ; Zhinan Chen^a ; ^{znchen@fmmu.edu.cn"" rel=""nofollow}
• 关键词：Single nucleotide polymorphism ; Colorectal cancer ; Prognosis
• 刊名：European Journal of Cancer
• 出版年：2011
• 出版时间：July 2011
• 年：2011
• 卷：47
• 期：11
• 页码：1699-1707
• 全文大小：273 K

文摘

Purpose

Extensive evidence has suggested that risk factors of cancer development may also modulate cancer clinical outcome. Recent genome-wide association (GWA) studies identified several single nucleotide polymorphisms (SNPs) predisposing to colorectal cancer (CRC). Given the pivotal importance of these variants in CRC, we sought to evaluate their associations with clinical outcomes of the disease.

Experimental Design

In a well-characterised cohort including 380 Chinese CRC patients, we genotyped seven SNPs identified in previous multi-stage GWA studies and analysed their associations with patient recurrence and survival.

Results

One SNP on chromosome 15q13, rs4779584 was associated with reduced risk of death with a hazard ratio (HR) of 0.33 (95 % confidence interval [CI] 0.15–0.72, P = 0.007). Another SNP in a gene-desert region on chromosome 10p14, rs10795668, was associated with a reduced risk of recurrence with an HR of 0.55 (95 % CI 0.30–1.00, P = 0.05). In a stratified analysis, this association was only evident in patients receiving chemotherapy (HR = 0.32, 95 % CI 0.14–0.78, P = 0.01, log rank P = 0.004), but not in those without chemotherapy (HR = 1.08, 95 % CI 0.43–2.73, P = 0.87, log rank P = 0.66). Moreover, we found that the effects of chemotherapy on CRC recurrence was only evident in patients with the variant-containing genotypes (HR = 0.35, 95 % CI 0.13–0.94, P = 0.04) but not in those with the wild-type genotype of rs10795668. Further analyses indicated a borderline significant interaction effect (P interaction = 0.05) between rs10795668 and chemotherapy on patient recurrence.

Conclusions

Our data suggested that rs10795668, a CRC susceptibility variant identified by GWA studies, might be used as a biomarker to identify CRC patients with high risk of recurrence after chemotherapy.